Armata Pharmaceuticals Pre-Tax Profit Margin 2006-2021 | ARMP

Armata Pharmaceuticals pre-tax profit margin from 2006 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Armata Pharmaceuticals Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $0.00B $-0.02B -575.00%
2021-06-30 $0.00B $-0.02B -800.00%
2021-03-31 $0.00B $-0.02B -1150.00%
2017-12-31 $0.00B $-0.01B inf%
2017-09-30 $0.00B $-0.02B inf%
2017-06-30 $0.00B $-0.02B inf%
2017-03-31 $0.00B $-0.02B inf%
2016-12-31 $0.00B $-0.02B inf%
2016-09-30 $0.00B $-0.01B inf%
2016-06-30 $0.00B $-0.00B inf%
2016-03-31 $0.00B $0.01B inf%
2015-12-31 $0.00B $-0.00B inf%
2015-09-30 $0.00B $0.00B inf%
2015-06-30 $0.00B $0.02B inf%
2015-03-31 $0.00B $0.02B inf%
2014-12-31 $0.00B $0.02B inf%
2014-09-30 $0.00B $0.02B inf%
2014-06-30 $0.00B $-0.04B inf%
2014-03-31 $0.00B $-0.07B inf%
2013-12-31 $0.00B $-0.06B inf%
2013-06-30 $0.00B $-0.01B -433.33%
2013-03-31 $0.01B $0.00B 14.29%
2009-12-31 $0.01B $0.01B 66.67%
2009-09-30 $0.01B $-0.01B -45.45%
2009-06-30 $0.01B $-0.01B -100.00%
2009-03-31 $0.01B $-0.02B -250.00%
2008-12-31 $0.01B $-0.02B -262.50%
2008-09-30 $0.01B $-0.02B -166.67%
2008-06-30 $0.01B $-0.02B -166.67%
2008-03-31 $0.01B $-0.02B -150.00%
2007-12-31 $0.01B $-0.02B -160.00%
2007-09-30 $0.01B $-0.01B -90.91%
2007-06-30 $0.01B $-0.01B -90.91%
2007-03-31 $0.01B $-0.03B -377.78%
2006-12-31 $0.01B $-0.03B -377.78%
2006-09-30 $0.01B $-0.04B -557.14%
2006-06-30 $0.01B $-0.04B -700.00%
2006-03-31 $0.01B $-0.02B -316.67%
2005-12-31 $0.01B $-0.02B -333.33%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.142B $0.001B
Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88